Phase II
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
Shares of New Jersey-based Advaxis have plunged more than 28 percent in premarket trading after the company quietly disclosed that Amgen terminated its collaboration on an immuno-oncology program. The deal between the two companies was first inked in 2016 and had a value of up to $540 million.
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
KaNDy Therapeutics, a clinical-stage company developing a potential breakthrough non-hormonal treatment for multiple debilitating symptoms of the menopause, today announces initiation of the Phase 2b clinical trial evaluating NT-814 in women with troublesome symptoms of the menopause.
White Americans make up the vast majority of clinical trial participants, despite evidence that some cancers affect minority populations in greater numbers.
There is very little doubt that developing drugs for neuroscience disorders in general and dementias in particular is a high-risk business. Axovant Sciences, unfortunately, seems to be finding that out the hard way.
Pharming Group N.V. today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).
Favorable safety and statistically significant efficacy demonstrated in a completed randomized, double-blind, placebo-controlled induction clinical trial based on clinical and endoscopic endpoints
Elafibranor successfully meets primary endpoint with high statistical significance of p<0.001
Phase 2 study targeting a patient population with NASH-induced Stage 2 or 3 fibrosis
PRESS RELEASES